26 completed, 9 terminated, 2 active not recruiting, 2 withdrawn. 41 Phase 2, 11 Phase 3, 2 Phase 1.
Follow Aspergillosis: new trials by email Literature Review of Aspergillosis trials Research Report on Aspergillosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B) - Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis | Phase 2 | Completed | Radboud University Medical Center | 10 | 2025-05-01 | 2026-08-18 |
| Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care, Antifungals as standard of care - Chronic Pulmonary Aspergillosis, Aspergillosis | Phase 2 | Active not recruiting | Manchester University NHS Foundation Trust | 50 | 2024-05-17 | 2026-08-18 |
| Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA Itraconazole Powder, Placebo - ABPA | Phase 2 | Terminated | Pulmatrix Inc. | 8 | 2023-02-01 | 2024-04-02 |
| An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study) Opelconazole, Standard of Care - Pulmonary Aspergillosis | Phase 2 | Completed | Pulmocide Ltd | 102 | 2021-11-19 | 2026-04-30 |
| A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection Posaconazole 100 MG [Noxafil], Posaconazole 40 MG/ML - Cystic Fibrosis, Aspergillosis | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 135 | 2021-04-22 | 2021-07-19 |
| Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) dupilumab, Placebo - Allergic Bronchopulmonary Aspergillosis | Phase 2 | Completed | Regeneron Pharmaceuticals | 62 | 2020-09-15 | 2025-04-04 |
| Deflazacort Vs. Prednisolone in Acute-stage ABPA Deflazacort, Prednisolone - Allergic Bronchopulmonary Aspergillosis | Phase 2 / Phase 3 | Active not recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 150 | 2020-01-15 | 2025-02-28 |
| Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds fosmanogepix - Invasive Fungal Infections | Phase 2 | Terminated | Basilea Pharmaceutica | 21 | 2020-01-04 | 2025-09-16 |
| The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. PC945, Standard of Care - Aspergillosis, Lung Transplant Infection | Phase 2 | Terminated | Pulmocide Ltd | 2 | 2019-09-17 | 2021-07-16 |
| Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis PUR1900, Placebo - Allergic Bronchopulmonary Aspergillosis | Phase 2 | Terminated | Pulmatrix Inc. | 7 | 2019-07-31 | 2021-08-27 |
| The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis PC945 - Aspergillosis, Cystic Fibrosis | Phase 2 | Terminated | Pulmocide Ltd | 4 | 2019-04-03 | 2021-07-16 |
| Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis SCY-078, Voriconazole, Oral Placebo Tablets - Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Scynexis, Inc. | 22 | 2019-01-22 | 2024-08-09 |
| VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B - Invasive Aspergillosis, Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Vical | 4 | 2018-02-20 | 2019-02-27 |
| Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients F901318, Caspofungin - Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | F2G Ltd | 2017-04-20 | 2018-02-15 | |
| A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma Glucocorticoids, Vitamin D - Allergic Bronchopulmonary Aspergilloses | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 30 | 2016-12-01 | 2018-08-23 |
| Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). Liposomal amphotericin B (Ambisome®), placebo - Allergic Bronchopulmonary Aspergillosis | Phase 2 | Completed | Poitiers University Hospital | 174 | 2014-11-19 | 2020-06-09 |
| Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy VFEND - Immunocompromised Patient, Aspergillosis | Phase 2 | Suspended | Brynn Chappell | 33 | 2014-09-01 | 2015-10-07 |
| ATCF (Azole Therapy in Cystic Fibrosis) Itraconazole/voriconazole - Cystic Fibrosis, Aspergillus Infections | Phase 2 | Completed | Rennes University Hospital | 11 | 2014-06-01 | 2023-05-24 |
| A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis Itraconazole, Glucocorticoids - Allergic Bronchopulmonary Aspergillosis | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 191 | 2014-05-01 | 2022-10-07 |
| Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis Prednisolone, Voriconazole - Allergic Bronchopulmonary Aspergillosis | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 50 | 2013-06-01 | 2017-12-12 |
Showing 20 of 41. Sign in to see all of them.
Aspergillosis, Allergic Bronchopulmonary (13) · Mycoses (7) · Invasive Pulmonary Aspergillosis (5) · Cystic Fibrosis (4) · Pulmonary Aspergillosis (4) · Asthma (3) · Candidiasis (3) · Invasive Fungal Infections (3) · Leukemia (2) · COVID-19 (1) · Candidiasis, Invasive (1) · Cryptococcosis (1) · Granulomatous Disease, Chronic (1) · Hematologic Diseases (1)
Bacterial Infections and Mycoses (41) · Infections (41) · Mycoses (34) · Lung Diseases (24) · Respiratory Tract Diseases (24) · Lung Diseases, Fungal (20) · Pulmonary Aspergillosis (16) · Immune System Diseases (15) · Respiratory Tract Infections (15) · Hypersensitivity (13) · Hypersensitivity, Immediate (13) · Respiratory Hypersensitivity (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5)
Caspofungin (7) · Voriconazole (7) · Itraconazole (5) · Glucocorticoids (4) · liposomal amphotericin B (4) · Micafungin (3) · Prednisolone (3) · Standard of Care (3) · Azoles (2) · Amphotericin B (1) · Anidulafungin (1) · Antifungal Agents (1) · Injections (1) · Steroids (1) · Suspensions (1)
Post Graduate Institute of Medical Education and Research, Chandigarh (7) · Merck Sharp & Dohme LLC (4) · Pfizer (3) · Pulmocide Ltd (3) · Astellas Pharma Inc (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Pulmatrix Inc. (2) · Bambino Gesù Hospital and Research Institute (1) · Basilea Pharmaceutica (1) · Brynn Chappell (1) · Erasmus Medical Center (1) · F2G Ltd (1) · Fundació Sant Joan de Déu (1) · Manchester University NHS Foundation Trust (1) · Northern Italy Leukemia Group (1)
United States (13) · United Kingdom (11) · France (9) · Germany (9) · India (8) · Belgium (5) · Netherlands (4) · Canada (3) · Italy (3) · Poland (3) · Spain (3) · Australia (2) · Ireland (2) · Japan (2) · Romania (2)
Ritesh Agarwal, MD, DM (2) · A Vulto, PhD (1) · Adilia Warris, Prof (1) · Bart JA Rijnders, MD, PhD (1) · Chiara Cattaneo (1) · Chris Cabell, MD (1) · Chris Kosmidis, MD (1) · David Angulo, MD (1) · David Denning, FRCP, FRC Path, FIDSA, FMedSci (1) · Elias Anaissie, MD (1) · Giuseppe Rossi, MD (1)
PMID 16436724, PMID 16678903, PMID 18983417, PMID 21729932, PMID 21911573, PMID 23335740, PMID 25451051, PMID 25701307, PMID 26585431, PMID 29331473, PMID 30049743, PMID 30561849, PMID 33027187, PMID 33293212, PMID 33680981, PMID 34764182, PMID 35822920, PMID 36836250, PMID 38387646, PMID 40203286, PMID 42845221
2018 (3), 2019 (3), 2009 (1), 2017 (1), 2023 (1)